Genfit (NASDAQ:GNFT) Shares Up 0.5% - Here's What Happened

Genfit S.A. (NASDAQ:GNFT - Get Free Report)'s stock price traded up 0.5% during mid-day trading on Wednesday . The stock traded as high as $4.33 and last traded at $4.31. 4,791 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 14,656 shares. The stock had previously closed at $4.29.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Genfit in a research report on Friday, February 7th.

Genfit Stock Performance

The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74. The stock has a 50-day moving average price of $3.82 and a two-hundred day moving average price of $3.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genfit stock. OLD Mission Capital LLC acquired a new stake in shares of Genfit S.A. (NASDAQ:GNFT - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The fund acquired 22,238 shares of the company's stock, valued at approximately $76,000. 2.24% of the stock is currently owned by hedge funds and other institutional investors.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.